{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:07:27Z","timestamp":1779224847809,"version":"3.51.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1212\/wnl.52.4.782","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:38:48Z","timestamp":1336916328000},"page":"782-782","source":"Crossref","is-referenced-by-count":97,"title":["Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone"],"prefix":"10.1212","volume":"52","author":[{"given":"Patricia I.","family":"Rosebush","sequence":"first","affiliation":[{"name":"From the Department of Psychiatry and Behavioural Neurosciences (Drs. Rosebush and Mazurek) and the Department of Medicine (Neurology) (Dr. Mazurek)McMaster University Medical Centre, Hamilton, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Mazurek","sequence":"additional","affiliation":[{"name":"From the Department of Psychiatry and Behavioural Neurosciences (Drs. Rosebush and Mazurek) and the Department of Medicine (Neurology) (Dr. Mazurek)McMaster University Medical Centre, Hamilton, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb01473.x"},{"key":"e_1_3_2_3_2","first-page":"213","volume":"28","year":"1992","unstructured":"Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone : clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213\u2013218.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_2_4_2","first-page":"25","volume":"13","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.6.825"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.6.712"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_3_2_8_2","first-page":"534","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology (revised). Washington, DC, U.S. Department of Health, Education and Welfare, USGPO, 1976 volume:534\u2013537.","journal-title":"Department of Health, Education and Welfare, USGPO,"},{"key":"e_1_3_2_9_2","first-page":"486","volume":"39","year":"1982","unstructured":"Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486\u2013487.","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830220079011"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.6.799"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00447-8"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199804000-00003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-199805000-00006"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.10.2.220"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0205"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.3.417"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00011"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.5.708"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.1.122"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v57n1002"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00007"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.9.1.1"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120423"},{"key":"e_1_3_2_25_2","first-page":"681.","volume":"344","year":"1994","unstructured":"Ford B, Lynch T, Greene P. Risperidone in Parkinson\u2019s disease. Lancet 1994;344:681. Letter.","journal-title":"Lancet"},{"key":"e_1_3_2_26_2","first-page":"556","volume":"56","year":"1995","unstructured":"Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson\u2019s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556\u2013559.","journal-title":"J Clin Psychiatry"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.52.4.782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:37:09Z","timestamp":1711535829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.52.4.782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["10.1212\/WNL.52.4.782"],"URL":"https:\/\/doi.org\/10.1212\/wnl.52.4.782","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]}}}